DAXOR CORP Stock Price, News & Analysis

Daxor Corporation (NYSE: DXR) reported a remarkable 92.6% revenue growth driven by the successful commercialization of its BVA-100® Blood Volume Analyzer. Significant factors include the launch of 12 new accounts, a 9.2% price increase, and orders from the U.S. Department of Defense. The firm also disclosed net assets of $19.6 million per share, rising 35.3% year-over-year. Furthermore, Daxor is progressing on a new portable blood volume analyzer with FDA submission expected by year-end, projecting a 2023 launch.

Daxor Corporation (Nasdaq: DXR) will announce its financial results for the six months ending June 30, 2022, on August 25, 2022, at approximately 4:00 p.m. ET. The earnings conference call will be hosted by President and CEO Michael Feldschuh and CFO Robert Michel at 4:30 p.m. ET on the same day. Investors can participate in a Q&A session by submitting their questions via email. The conference call will also be available through a live webcast, with replay options until November 25, 2022. Daxor is recognized for its innovative blood volume measurement technologies.

Daxor Corporation (Nasdaq: DXR) reported a 49.4% increase in year-over-year sales of its single-use diagnostic kits. The company also achieved a 10.4% growth in sales from Q1 to Q2 2022, benefitting from new accounts and increased capital equipment purchases. Recent successes include a major acquisition at a leading Illinois academic center and expansion within a major South Carolina healthcare organization servicing 1.5 million patients. Ongoing clinical studies and contracts with the U.S. military are not included in these figures but are contributing additional revenue.

Daxor (Nasdaq: DXR) has partnered with MedAxiom to enhance the adoption of its blood volume analysis (BVA) technology. This collaboration aims to improve patient outcomes, reduce healthcare costs, and optimize clinician experiences as heart failure diagnoses rise. Daxor's BVA technology has demonstrated significant improvements in patient metrics, including an 82% decrease in 30-day mortality and enhanced treatment plans with 98% accuracy. The partnership leverages MedAxiom's extensive network to accelerate technology delivery in the cardiovascular community, aligning with healthcare’s Quadruple Aim.

Daxor Corporation (Nasdaq: DXR) has secured funding from the National Institute of Health (NIH) to enhance its clinical decision support software aimed at improving heart failure treatment.

The company participated in the NIH's Innovation Corps (I-Corps™) program, which supports businesses ready for commercialization of NIH-funded projects. This program provided vital resources to accelerate the launch of Daxor’s software, designed to optimize fluid management in acute heart failure.

Daxor Corporation (Nasdaq: DXR) has entered a Cooperative Research and Development Agreement with The Uniformed Services University and The Henry M. Jackson Foundation. The collaboration aims to develop a non-nuclear blood volume diagnostic device, enhancing the existing BVA-100 technology. This device is designed for both military and civilian use, targeting conditions like trauma and heart failure. Extensive studies validate Daxor's technology, showing a potential for improved patient outcomes by significantly enhancing fluid management in critical care.

Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, will exhibit at the American Association of Heart Failure Nurses 18th Annual Meeting from June 15-18, 2022, in Orlando, Florida. They aim to educate healthcare professionals on their blood volume technology, which reportedly reduces 30-day mortality by 82% and readmissions by 56%. Daxor has conducted over 60,000 tests across the U.S., contributing to better patient outcomes in various medical conditions, including heart failure.

Daxor Corporation (Nasdaq: DXR) announced its participation in a National Institutes of Health (NIH) study on neurologic function after COVID-19 infection, utilizing its BVA-100 technology. Led by Dr. Avindra Nath at the NIH's National Institute of Neurological Disorders and Stroke, the study aims to address lingering symptoms from COVID-19, such as 'brain fog.' CEO Michael Feldschuh highlighted the clinical utility of the BVA-100, which is commonly used in hospitals. Daxor is also developing a next-generation portable analyzer under contract with the Department of Defense.

Daxor Corporation (Nasdaq: DXR) will present at the H.C. Wainwright Global Life Investment Hybrid Conference from May 23-26, 2022, in Miami Beach, FL. CEO Michael Feldschuh will speak on May 25 at 4:30 PM ET, highlighting the company's achievements in financial performance, product commercialization, and collaborations with the U.S. Department of Defense and the National Institute of Health. Daxor's BVA-100® blood test is pivotal in managing critical care, COVID-19, and heart failure, with over 60,000 tests conducted. Interested parties can register for the event and request one-on-one meetings.